why choose us

300×250 Ad Slot

Drug FDA Status

Showing 30 of 144 result(s) (Page 3 of 15)
Drug Name: Ekterly

Active Ingredient: sebetralstat

Approval Date: 2025-07-03

Description: To treat acute attacks of hereditary angioedema
Drug Trials Snapshot

Drug Name: Lynozyfic

Active Ingredient: linvoseltamab-gcpt

Approval Date: 2025-07-02

Description: To treat relapsed or refractory multiple myeloma after at least four prior lines of therapy, including a proteasome inhibitor, an immunomodulatory agent, and an anti CD38 monoclonal antibody

Drug Name: Zegfrovy

Active Ingredient: sunvozertinib

Approval Date: 2025-07-02

Description: To treat locally advanced or metastatic non-small cell lung cancer with epidermal growth factor receptor exon 20 insertion mutations, as detected by an FDA-approved test, with disease progression on or after platinum-based chemotherapy

Drug Name: Andembry

Active Ingredient: garadacimab-gxii

Approval Date: 2025-06-16

Description: To prevent attacks of hereditary angioedema
Drug Trials Snapshot

Drug Name: Ibtrozi

Active Ingredient: taletrectinib

Approval Date: 2025-06-11

Description: To treat locally advanced or metastatic ROS1-positive non-small cell lung cancer
Drug Trials Snapshot

Drug Name: Enflonsia

Active Ingredient: clesrovimab-cfor

Approval Date: 2025-06-09

Description: To prevent respiratory syncytial virus (RSV) lower respiratory tract disease in neonates and infants who are born during or entering their first RSV season 
Drug Trials Snapshot

Drug Name: Tryptyr

Active Ingredient: acoltremon

Approval Date: 2025-05-28

Description: To treat the signs and symptoms of dry eye disease
Drug Trials Snapshot

Drug Name: Emrelis

Active Ingredient: telisotuzumab vedotin-tllv

Approval Date: 2025-05-14

Description: To treat locally advanced or metastatic, non-squamous non-small cell lung cancer (NSCLC) with high c-Met protein overexpression after prior systemic therapy 
Drug Trials Snapshot

Drug Name: Avmapki Fakzynja Co-Pack

Active Ingredient: avutometinib and defactinib

Approval Date: 2025-05-08

Description: To treat KRAS-mutated recurrent low-grade serous ovarian cancer (LGSOC) after prior systemic therapy
Drug Trials Snapshot

Drug Name: Imaavy

Active Ingredient: nipocalimab-aahu

Approval Date: 2025-04-29

Description: To treat generalized myasthenia gravis
Drug Trials Snapshot

300×250 Ad Slot